Related Experiment Video
Updated: Dec 25, 2025
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer
Trinh Le Huy1, My Hanh Bui2,3, Toi Chu Dinh4
1Department of Oncology, Hanoi Medical University Hospital, Hanoi, Vietnam.
Background:
In recent times, scientists have found new treatments for colorectal cancer patients.
Aim:
The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV.
Methods:
Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients.
Results:
The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage.
Conclusions:
The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
02:56Treatment Resistant Cancers